New Triple-Threat attack on advanced skin cancer
NCT ID NCT03149029
Summary
This study is testing whether a short course of two targeted cancer drugs (trametinib and dabrafenib), given alongside an immunotherapy drug (pembrolizumab), works better for people with advanced melanoma that cannot be removed by surgery. The goal is to see if this combination helps control the cancer for a longer period. All 16 participants have a specific genetic change (BRAF V600 mutation) in their cancer and have not received certain prior treatments for their advanced disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts general Hospital
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.